GRP与其受体预测小细胞肺癌远处转移的价值研究.pdfVIP

Isdeathreceptor4or5agoodtragetforcancer antibodytherapy? ZhengDe-xianLiuYan-xin InstituteofBasicMedicalSciences,ChinsesAcademyofMedicalSciences [Abstract] Tumornecrosisfactor-relatedapoptosis-inducingligand(TRAIL),amemberofthetumor necrosisfactorsuper-family,inducescelldeathuponbindingtoitsdeathreceptors(DR4andDR5)viaan intrinsicand/oranextrinsicsignalingpathway.Promisingly,DR4orDR5preferentiallymediatescelldeathin variouscancercellswithouttoxicitytomostnormalcells.Theseuniquecharactersofdeathreceptorsleadtothe developmentdeathreceptor-targetingcancertherapeutics,includingtheagonisticantibodiesagainstDR4orDR5. TherehavebeenseveralantibodiesagainstDR4orDR5inclinicaltrialsexhibitingapromisingforeground.We presentherethepreclinicalstudyofanovelanti-DR5monoclonalantibody,AD5-10,whichinducescelldeath invarioustumorcellsintheabsenceofsecondcross-linkingantibodyinvitroandastrongtumoricidalactivityin vivo.AD5-10doesnotcompetewithitsnativeligandTRAILforbindingtoDR5,butcontrarilysynergizeswith TRAILtoinducecelldeathinvariouscancercells.Preclinicalstudydemonstratedthattheremodeledantibodies (scFv,chimericandhumanizedaswellasviralexpressedantibody)ofAD5-10showedastrongcytotoxicityto thecancercellsofliver,lung,colon,leukemia,breastandovarybothinvitroandinvivo.Thesedataindicatethat remodeledantibodyofAD5-10couldbeapromisingtherapeuticforcancers. GRP及其受体预测小细胞肺癌远处转移的价值研究 苏景伟 祝淑钗 王玉祥 刘志坤 沈文斌 李娟 河北医科大学第四医院放疗科 [摘要] 目的 探讨小细胞肺癌肿瘤标记物与局部控制、预后及远处转移的关系及预测远处转移 的价值。方法 回顾性分析73例小细胞肺癌患者临床及病理资料，接受手术治疗者38例(52.1％)， 局部放疗者35例(47.9％)。用免疫组化法检测NSE、GRP、GRPR的蛋白表达，结合肿瘤体积重新 分级，分析其与小细胞肺癌患者预后、局部控制、远处转移的关系。结果 NSE、GRP、CRPR蛋 白在小细胞肺癌组织中的阳性表达率分别为71.2％、79.5％、75.3％，GRP与GRPR的表达存在相关性 (P=0.000)。GRP、GRPR蛋白不同表达水平患者间的预后及远处转移均存在明显差异(P＜0.05)。 GRP与GRPR蛋白表达预测小细胞肺癌远处转移的灵敏度均为71.4％，特异度分别为83.9％、90.3％。结 论 GRP、GRPR是灵敏度及特异度均较好的预测小细胞肺癌的侵袭性及远处转移的重要指标。 [关键词]小细胞肺